The Views of 1,500 Patient Groups on the Pharmaceutical Industry and ESG (Environmental, Social, and Governance) - ResearchAndMarkets.com
Retrieved on:
Wednesday, December 14, 2022
Pharmaceutical, Professional Services, Health, Environmental, Social and Governance (ESG), Pharma, Vaccine, Biophysical environment, Pharma Nord, Environment, Patient, ESG, Climate change, International, Environmental, social and corporate governance, Growth, Lithium, Medicine, Generic drug, Pharmaceutical industry, Medical device
Many of these patient groups feel that pharma companies could do much more to communicate their ESG strategies to patient groups.
Key Points:
- Many of these patient groups feel that pharma companies could do much more to communicate their ESG strategies to patient groups.
- Other respondent patient groups acknowledge the potential of ESG to support companies' efforts at building more patient-centric measures of company performance.
- - International blood-cancers patient group, Romania
Looking to the future, many patient groups would like pharma companies to improve how they involve patient communities in defining patient-relevant ESG measures. - A significant number (140) of respondent patient groups offered their own criteria for pharma's ESG targets [details provided in the 'Pharma and ESG - the Patient Perspective' report].